Effect of antisense inhibition of urokinase receptor on malignancy

Current Topics in Microbiology and Immunology

Volumn 213 III, Issue , 1996, Pages 101-112

  Ossowski, L ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY RNA; PLASMINOGEN ACTIVATOR INHIBITOR; UNCLASSIFIED DRUG; UROKINASE RECEPTOR; UROKINASE TYPE PLASMINOGEN ACTIVATOR RECEPTOR;

DRUG TARGETING; ENZYME INHIBITION; GENE EXPRESSION REGULATION; HUMAN; METASTASIS; PRIORITY JOURNAL; REVIEW;

EID: 0030005518     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-642-80071-9_7     Document Type: Review

References (65)

1. Anchini E, Fibbi G, Pucci M, Caldini R, Chevanne M, Del Rosso M (1994) Production of second messengers following chemotactic and mitogenic urokinase-receptor interaction in human fibroblasts transfected with human urokinase receptor. Exp Cell Res 213: 438-448
2. Axelrod JH, Reich R, Miskin R (1989) Expression of human recombinant plasminogen activators enhances invasion and experimental metastasis of H-ras-transformed NIH 3T3 cells Mol Cell Biol 9: 2133-2141
3. Behrendt N, Ploug M, Patthy L, Houen G, Blasi F, Dano K (1991) The ligand binding domain of the cell surface receptor for urokinase-type plasminogen activator. J Biol Chem 266: 7842-7847
4. Bianchi E, Cohn RL, Thor AT, Todd RF 3rd, Mizukami IF, Lawrence DA, Ljung BM, Shuman MA, Smith HS (1994) The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. Cancer Res 54: 861-866
5. Busso N, Masur SK, Lazega D, Waxman S, Ossowski L (1994) Induction of cell migration by pro-urokinase binding to its receptor. possible mechanism for signal transduction J Cell Biol 126 259-270
6. Carmeliet P, Schoonjans L, Kieckens L, Ream B, Degen J, Bronson R, Devos R, van den Ord J, Collen D, Mulligan R (1994) Physiological consequences of the loss of plasminogen activator gene formation in mice. Nature 368: 419-424
7. Carriero MV, Franco P, Del-Vecchio S, Massa O, Botti G, D'Aiuto G, Stoppelli MP, Salvatore M (1994) Tissue distribution of soluble and receptor bound urokinase in human breast cancer using a panel of monoclonal antibodies. Cancer Res 54: 5445-5454
8. Crowley CW, Cohen R, Lucas BK, Liu G, Shuman MA, Levinson AD (1993) Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90: 5021-5025
9. Cubellis MV, Andreasen P, Ragno P, Mayer M, Dano K, Blasi F (1989) Accessibility of receptor-bound urokinase to type-1 palsminogen activator inhibitor Proc Natl Acad Sci USA 86: 4828-4834
10. Dano K, Andreasen PA, Grondahl-Hansen J, Kristensen P, Nielsen L, Skriver L (1985) Plasminogen activators, tissue degradation and cancer Adv Cancer Res 44: 139-266
11. DeBrum PA, Griffioen G, Verspaget HV, Verheijen JH (1987) Plasminogen activators and tumor development in the human colon Activity levels in normal mucosa, adenomateous tissue, polyps and adenocarcinomas. Cancer Res 47 4654-4657
12. Del Rosso M, Anichini E, Pedersen N, Blasi F, Fibbi G, Pucci M, Ruggiero M (1993) Urokinase-urokinase receptor interaction non-mitogenic signal transduction in human epidermal cells Biochem Biophys Res Commun 190: 347-352
13. Duffy MJ, Reilly D, O'Sullivan C, O'Higgins N, Fennely JJ (1990) Urokinase plasminogen activator and prognosis in breast cancer. Lancet 13 108-111
14. Dumler I, Petri T, Schleuning W-D (1993) Interaction of urokinase-type plasminogen activator (uPA) with its cellular receptor (uPAR) induces phosphorylation on tyrosine of a 38 kDa protein FEBS Lett 322: 37-40
15. Dumler I, Petri T, Schleuning W-D (1994) Induction of c-fos gene expression by urokinase-type plasminogen activator in human ovarian cancer cells. FEBS Lett 343: 103-106
16. Fibbi G, Ziche M, Morbidelli L, Magnelli L, Del Rosso M (1988) Interaction of Urokinase with specific receptors stimulates mobilization of bovine adrenal capillary endothelial cells. Exp Cell Res 179 385-395
17. Goodson RJ, Doyle MV, Kaufman SE, Rosenberg S (1994) High affinity urokinase receptor antagonists identified with bacteriophage peptide display. Proc Natl Acad Sci USA 91: 7129-7133
18. Grondahl-Hansen J, Ralfkiaer E, Kirkeby L, Kristensen P, Lund LR, Dano K (1991) Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Am J Pathol 138: 111-117
19. Grondahl-Hansen J, Christensen IJ, Rosenquist C, Brunner N, Mouridsen HT, Dano K, Blichert-Toft M (1993) High levels of urokinase-type palsminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53: 2513-2521
20. Gudewicz PW, Gilboa N (1987) Human urokinase-type plasminogen activator stimulates chemotaxis of human neutrophils. Biochem Biophys Res Commun 147: 1176-1181
21. Hearing VJ, Law LW, Corti A, Appella E, Blasi F (1988) Modulation of metastatic potential by cell surface urokinase of murine melanoma cells. Cancer Res 48: 1270-1278
22. Hollas W, Blasi F, Boyd D (1991) Role of urokinase receptor in facilitating extracellular matrix invasion by cultured coton cancer. Cancer Res 51 3690-3695
23. Janicke F, Schmidt M, Hollrieder A, Babic R, Ulm K, Gossner W, Graeff H (1990) Urokinase-type plasminogen activator (uPA) is a predictor of early relapse in breast cancer. Fibrinolysis 4: 69-78
24. Janicke F, Graeff H, Schmitt M (1991) Clinical relevance of urokinase-type and tissue-type plasminogen activators and their type 1 inhibitor in breast cancer Semin Thromb Hemost 17: 303-312
25. Kariko K, Megyeri K, Xiao Q, Barrnathan ES (1994) Lipofectin aided cell delivery of ribozyme targeted to human urokinase receptor mRNA. FEBS Lett 352: 41-44
26. Kirchheimer JC, Remold HG (1989) Functional characteristic of receptor-bound urokinase on human monocytes: catalytic efficiency and susceptibility to inactivation by plasminogen activator inhibitors. Blood 74: 1396-1402
27. Kobayashi H, Fujishiro S, Terao T (1994) Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis tn cervical cancer Cancer Res 54: 6539-6548
28. Kobayashi H, Gotoh J, Fujie M, Shinohara H, Moniwa N, Terao T (1994) Inhibition of metastasis of Lewis lung carcinoma by a synthetic peptide within growth factor domain of urokinase in the experimental and spontaneous metastasis model Int J Cancer 57. 727-733
29. Kook Y-H, Adamsk J, Zelent A, Ossowski L (1994) The effect of antisense inhibition of urokinase receptor in human squamous cell carcinoma on malignancy. EMBO J 13: 3983-3991
30. Liu G, Shuman MA, Cohen RL (1995) Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cells Int J Cancer 60. 501-506
31. Lu H, Yeh P, Guitton JD, Mabilat C, Desanlis F, Maury I, Legrand Y, Soria J, Sona C (1994) Blockage of the urokinase receptor on the cell surface: construction and characterization of hybrid protein consisting of the N-terminal fragment of human urokinase and human albumin. FEBS Lett 356. 56-59
32. Markus G (1988) The relevance of plasminogen activators to neopalstic growth Enzyme 40 158-172
33. Mignatti P, Rifkin DB (1993) Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73: 161-195
34. Mignatti P, Robbins E, Rifkin DB (1986) Tumor invasion through the human amniotic membrane: requirement of proteinase cascade. Cell 47: 487-498
35. Moroni MC, Willingham MC, Beguinot L (1992) EGF-R antisense blocks expression of the epidermal growth factor receptor and suppresses the transformed phenotype of a human carcinoma cell line. J Biol Chem 267. 2714-2722
36. Odekon LE, Sato Y, Rifkin DB (1992) Urokinase-type palsminogen activator mediates basic fibroblast growth factor-induced bovine endothelial cell migration independent of its proteolytic activity. J Cell Physiol 150. 258-263
37. Ossowski L (1988a) Plasminogen activator dependent pathways in the dissemination of human tumor cells in the chick embryo. Cell 52: 321-328
38. Ossowski L (1988b) In vivo invasion of modified membrane by tumor cells the role of cell surface-bound urokinase. J Cell Biol 107. 2437-2445
39. Ossowski L (1992) Invasion of connective tissue by human carcinoma cell lines: requirement for urokinase, urokinase receptor, and interstitial collagenase. Cancer Res 52: 6754-6760
40. Ossowski L, Reich E (1980) Experimental model for quantitative study of metastasis. Cancer Res 40: 2300-2309
41. Ossowski L, Reich E (1983) Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35: 611-619
42. Ossowski L, Russo-Payne H, Gartner M, Wilson EL (1987) Inhibition of urokinase-type plasminogen activator by antibodies: the effect of dissemination of human tumor in the nude mouse. Cancer Res 51: 274-281
43. Osswski L, Clunie G, Masucci T, Blasi F (1991) In vivo paracrine interaction between urokinase and its receptor: effect on tumor cell invasion J Cell Biol 115: 1107-1112
44. Pyke C, Graem N, Ralfkiaer E, Hoyer-Hansen G, Brunner N, Dano K (1993) Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma Cancer Res 53: 1911-1915
45. Pyke C, Kristensen P, Ralkfiaer E, Ronne E, Grondahl-Hansen J, Eriksen J, Blasi F, Dano K (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells in invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067
46. Quattrone A, Fibbi G, Anichini E, Pucci M, Zamperini A, Capaccioli S, Del Rosso M (1995) Reversion of the invasive phenotype of transformed human fibroblasts by anti-messenger oligonucleotide inhibition of urokinase receptor gene expression. Cancer Res 55: 90-95
47. Quax PHA, Padersen N, Masucci MT, Weeningverhoeff EJD, Dano K, Verheijnen JH, Blasi F (1991) Complementation between urokinase-producing and receptor-producing cells in extracellular matrix degradation. Cell Regul 2: 793-803
48. Raschella G, Negroni A, Skorski T, Puces S, Nieborowska-Skorska M, Romeo A, Calabretta B (1992) Inhibition of proliferation by c-myb antisense RNA and Oligonucleotides in transformed neuroectodermal cell lines. Cancer Res 52: 4221-4226
49. Reich R, Thompson EW, Iwamoto Y, Martin GR, Deason JR, Fuller GC, Miskin R (1988) Effect of inhibitors of plasminogen activator, serine proteinases and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 48. 3307-3312
50. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Dano K, Appela E, Blasi F (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface plasmin-dependent proteolysis. EMBO J 9. 467-474
51. 2 amino terminal domain of urokinase receptor. FEBS Lett 288: 233-236
52. Sappino AP, Busse N, Belin D, Vassalli J-D (1987) Increase of urokinase-type plasminogen activator gene expression in human lung and breast carcinomas Cancer Res 47. 4043-4046.
53. Sappino A-P, Belin D, Huarte J, Hirschel-Scholtz S, Saurat J-H, Vassalli J-D (1991) Differential protease expression by cutaneous squamous and basal cell carcinomas. J Clin Invest 88: 1073-1079
54. Schlechte W, Murano G, Boyd D (1989) Examination of the role of urokinase receptors in human colon cancer mediated laminin degradation. Cancer Res 49: 6064-6069
55. Sim P-S, Stephens RW, Fayle DRH, Doe WF (1988) Urokinase-type plasminogen activator in colorectal carcinomas and adenomatous polyps: quantitative expression of active and proenzyme. Int J Cancer 42: 483-488
56. Solberg H, Romer J, Brunner N, Sidenius N, Dano K, Hoyer-Hansen G (1994) A cleaved form of the receptor for urokinase-type plasminogen activator in invasive translated human and murine tumors. Int J Cancer 58: 877-881
57. Stahl A, Mueller BM (1994) Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. Cancer Res 54: 3066-3071
58. Stoppelli MP, Corti A, Sofientini A, Cassani G, Blasi F, Assoian RK (1985) Differentiation-enhanced binding of the amino terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes Proc Nati Acad Sci USA 82: 4939-4943
59. Testa JE, Quigley JP (1990) The role of plasminogen activator in aggressive tumor behavior Cancer Metastasis Rev 9: 353-367
60. Toolan HW (1954) Transplantable human neoplasms maintained in cortisone-treated laboratory animals: HS#1, H E.p#1, H.Ep #2, H Ep.#3 and H Emb.#1. Cancer Res 14 660-666
61. Vassalli J-D, Baccino D, Belin (1985) A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100 86-92
62. Wei Y, Waltz DA, Drummond RJ, Rosenberg S, Chapman HA (1994) Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269: 32380-32388
63. Wilhelm O, Weidle U, Hohl S, Rottenberger P, Schmitt M, Graeff H (1994) Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator. Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 337: 131-134
64. Wolf BB, Gibson CA, Kapur V, Hussaini IM, Musser JM, Gonias SL (1994) Proteolytically active streptococcal pyrogenic exotoxin B cleaves monocytic cell urokinase receptor and releases an active fragment of the receptor from the cell surface. J Biol Chem 269. 30682-30687
65. Yu H, Schultz RM (1990) Relationship between secreted urokinase plasminogen activator activity and metastatic potential in murine B 16 cells transfected with human urokinase sense and antisense genes. Cancer Res 50: 7623-7633